working groups

ENS@T operates in four core Working Groups

ACC Working Group

Massimo Terzolo, MD
Head of Department of Internal Medicine I
University of Torino
Regione Gonzole 10
Torino, Italy

Period in office: 2019-2022

Scientific Board:
Guillaume Assie, Paris, France
Martin Fassnacht, Würzburg, Germany
Enzo Lalli, Nice, France
Michaela Luconi, Florence, Italy
Cristina Ronchi, Birmingham, UK

period in office: 2018-2021



Pheo/PPGL Working Group

Mercedes Robledo, PhD
Hereditary Endocrine Cancer, Group Leader
Human Cancer Genetics Programme
Spanish National Cancer Centre (CNIO)
C/ Melchor Fernández Almagro 3
Madrid, Spain

Mercedes Robledo is the head of the Hereditary Endocrine Cancer Group, in the Human Genetics Cancer Program at the Spanish National Cancer Center (CNIO), Madrid, Spain. Her Group is interested in identifying high and low genetic risk factors involved in pheochromocytoma and thyroid cancer susceptibility. To this end, we analyse tumour samples and look for differences between genomic features according to the different individual genetic backgrounds. Such comprehensive characterisation allows us, not only to define diagnostic and prognostic markers associated with primary mutations, but also to pinpoint specific altered pathways that can lead to the identification of future therapeutic targets.

Period in office: 2017-2020

Scientific Board:
Henri Timmers, Nijmegen, The Netherlands
Judith Favier, Paris, France
Anne-Paule Gimenez-Roqueplo, Paris, France
Elena Rapizzi, Florence, Italy
Rodrigo Toledo, Barcelona, Spain

period in office: 2017-2021


APA Working Group

Martin Reincke, MD

Medizinische Klinik und Poliklinik IV
University Hospital Munich
Ziemssenstr. 1
Munich, Germany

Martin Heinrich Reincke is the director of the Medizinische Klinik and Poliklinik IV, Ludwig-Maximilians University in Munich and Chair of the Department of Endocrinology and Diabetology..

His research focus includes adrenal physiology and pathophysiology, endocrine hypertension, pituitary disease, mineralocorticoid and glucocorticoid action and stress research. Professor Reincke is heading a research team specifically exploring the prevalence and relevance of mineralocorticoid excess in resistant hypertension on the epidemiological, clinical, genetic and molecular level.

Professor Reincke is a member of many national and international societies, including the Endocrine Society, European Society of Endocrinology and European Network of the study of adrenal tumors. He has served in the Executive Board of the German Endocrine Society and European Society of Endocrinology, is on the editorial board of several international journals, and has served as teaching dean of the faculty from 2006-2012.

He has published more than 380 Medline listed publications cited >9200 times, his h-index is 53.

Period in office: 2017-2020

Scientific Board:
Marcus Quinkler, Berlin, Germany
Tracy Williams, Torino, Italy
Jacques Lenders, Nijmegen, The Netherlands
Mitsuhide Naruse, Kyoto, Japan
Aleksander Prejbisz, Warsaw, Poland

period in office: 2017-2021


NAPACA Working Group

Wiebke Arlt, MD, DSc., FRCP, FMedSci
Institute of Metabolism and Systems Research (IMSR)
University of Birmingham
& Centre for Endocrinology, Diabetes and Metabolism (CEDAM)
Birmingham Health Partners
Birmingham, UK

Professor Wiebke Arlt is William Withering Chair of Medicine and Director of the Institute of Metabolism and Systems Research at the University of Birmingham, UK. She leads a multi-disciplinary research group focussing on steroid endocrinology in the context of adrenal and gonadal disorders. She is a Consultant Endocrinologist at the Queen Elizabeth Hospital Birmingham, where she serves as the Lead of the Adrenal Tumour Specialist Service. Her main interests are adrenal incidentaloma, adrenocortical carcinoma and adrenal steroid excess syndromes.

Period in office: 2017-2021

Scientific Board:
Iacopo Chiodini, Milano, Italy
Guido di Dalmazi, Bologna, Italy
Martin Fassnacht, Würzburg, Germany
Darko Kastelan, Zagreb, Croatia
Cristina Ronchi, Birmingham, UK

period in office: 2019-2022